The article provides an overview of the global landscape of COVID-19 vaccine development as of April 8, 2020. The genetic sequence of SARS-CoV-2 was published on January 11, 2020, leading to intense global R&D efforts. The Coalition for Epidemic Preparedness Innovations (CEPI) is supporting vaccine development through various initiatives. As of April 8, 2020, 115 vaccine candidates were in development, with 78 confirmed active projects, 73 of which are in exploratory or preclinical stages. The most advanced candidates, such as mRNA-1273 from Moderna and Ad5-nCoV from CanSino Biologicals, have recently entered clinical trials. The diversity of technology platforms includes nucleic acid, virus-like particles, viral vectors, and recombinant proteins. The article highlights the potential of novel platforms like DNA and mRNA for faster development and manufacturing. Adjuvants are also being considered to enhance immunogenicity and reduce dosing. Most active vaccine candidates are being developed by private/industry developers, with 56 out of 78 projects led by private entities. North America leads in vaccine development, followed by China, Asia (excluding China), and Europe. The authors emphasize the need for international coordination and cooperation to ensure equitable access to vaccines, particularly in low-resource regions. They also discuss the challenges and risks associated with accelerated vaccine development and the importance of robust evaluation of effectiveness and safety.The article provides an overview of the global landscape of COVID-19 vaccine development as of April 8, 2020. The genetic sequence of SARS-CoV-2 was published on January 11, 2020, leading to intense global R&D efforts. The Coalition for Epidemic Preparedness Innovations (CEPI) is supporting vaccine development through various initiatives. As of April 8, 2020, 115 vaccine candidates were in development, with 78 confirmed active projects, 73 of which are in exploratory or preclinical stages. The most advanced candidates, such as mRNA-1273 from Moderna and Ad5-nCoV from CanSino Biologicals, have recently entered clinical trials. The diversity of technology platforms includes nucleic acid, virus-like particles, viral vectors, and recombinant proteins. The article highlights the potential of novel platforms like DNA and mRNA for faster development and manufacturing. Adjuvants are also being considered to enhance immunogenicity and reduce dosing. Most active vaccine candidates are being developed by private/industry developers, with 56 out of 78 projects led by private entities. North America leads in vaccine development, followed by China, Asia (excluding China), and Europe. The authors emphasize the need for international coordination and cooperation to ensure equitable access to vaccines, particularly in low-resource regions. They also discuss the challenges and risks associated with accelerated vaccine development and the importance of robust evaluation of effectiveness and safety.